New RSV prevention strategy for infants under study in bogotá
NCT ID NCT07279298
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will check how well two RSV prevention methods work in real life: a vaccine given to pregnant women and an antibody shot given to newborns. Researchers will follow about 1,100 infants under 6 months old who are hospitalized with severe respiratory infections in Bogotá, Colombia. The goal is to see if these immunizations reduce severe RSV cases and hospital stays.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RSVpreF vaccine (Abrysvo) and nirsevimab (Beyfortus)
What this could lead to
If effective, these immunizations could prevent severe RSV infections in young infants, reducing hospitalizations and deaths.
What could go wrong
This is an observational study, not a controlled trial, so results may be less certain. Effectiveness may vary in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••